BIOSTATISTICS IN CLINICAL TRIALS
Kate Francis, Biostatistician (Snr Research Officer)
Murdoch Children’s Research Institute &
Honorary Research Fellow,
Department of Paediatrics, University of Melbourne &
Affiliate Biostatistician,
The Royal Children’s Hospital,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | July 2025
Kate Francis is a biostatistician with the Murdoch Children’s Research Institute (MCRI), an Honorary (Senior Fellow) within Department of Paediatrics, the University of Melbourne and Affiliate biostatistician with Royal Children’s Hospital in Narrm (Melbourne), Australia.
As a biostatistician working in research and clinical settings, she plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
Kate is also an expert in the measurement of adolescent health behaviours, determinants, and outcomes and this was recognised with her invitation to be a commissioner for the second Lancet Commission on Adolescent Health and Wellbeing which was recently released at the 2025 World Health Assembly meeting.
Kate believes in the importance of gender equity, diversity, and inclusion and was key team member in helping MCRI achieve bronze accreditation in the Science in Australia Gender Equity (SAGE) program.
Source: Supplied
-
Patient reported outcomes in the diagnosis and treatment of lymphoma
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
-
Identification, characterisation and role of leader cells in ovarian cancer progression
Dr. Maree Bilandzic is a molecular cancer biologist dedicated to advancing the understanding and treatment of ovarian cancer (OC). Her research addresses critical gaps in OC treatment by investigating the mechanisms behind metastasis, chemotherapy resistance, and tumour recurrence. By utilising innovative methodologies and disease-representative models, Dr. Bilandzic has pioneered the identification and characterisation of leader cells (LCs)—a unique, stem-like subpopulation within tumours that plays a crucial role in OC progression.
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
